{"title":"her2 -低表达与her2 -零表达非特殊型浸润性乳腺癌临床病理特征及预后意义的比较分析","authors":"Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han","doi":"10.4103/jcrt.jcrt_277_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.</p><p><strong>Methods: </strong>Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.</p><p><strong>Results: </strong>Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).</p><p><strong>Conclusion: </strong>The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 2","pages":"425-434"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.\",\"authors\":\"Yuanyuan Chen, Xin Ye, Jie Wang, Baosan Han\",\"doi\":\"10.4103/jcrt.jcrt_277_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.</p><p><strong>Methods: </strong>Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.</p><p><strong>Results: </strong>Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).</p><p><strong>Conclusion: </strong>The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.</p>\",\"PeriodicalId\":94070,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":\"21 2\",\"pages\":\"425-434\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_277_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_277_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Comparative analysis of the clinicopathological features and prognostic implications of invasive breast carcinoma of nonspecial type exhibiting HER2-low and HER2-zero expressions.
Purpose: This retrospectively study aimed to investigate the clinicopathological features, treatments, prognostic differences, and influencing factors between invasive breast carcinoma of nonspecial type (IBC-NST) with low and zero HER2 expressions.
Methods: Clinical data of patients with IBC-NST exhibiting low and zero HER2 expression were obtained from the Shanghai Jiao Tong University Breast Cancer Database spanning July 2009 to December 2019. The Kaplan-Meier method, log-rank test and Cox regression analyses were performed.
Results: Of the 2071 patients with IBC-NST, 1618 (78.1%) had low HER2 expression and 453 (21.9%) had zero HER2 expression. A higher proportion of patients aged below 40 years, with Ki67 >20%, and with tumor grade III were observed in the HER2-zero group. Higher percentages of estrogen receptor-positive, progesterone receptor-positive, hormone receptor (HR)-positive, and receipt of endocrine therapy were observed in the HER2-low group. The breast cancer-free interval (BCFI) and overall survival (OS) were similar between the groups. In the HR-positive subgroup, no significant differences were observed in the clinical pathological characteristics, treatment types, BCFI, and OS. In the HR-negative subgroup, higher proportions of patients aged over 40 years and patients in the postmenopausal stage were observed in the HER2-low group. Multivariate analysis revealed that the lymph node stage (N2-N3) was an independent risk factor for BCFI and OS regardless of the HER2 status. Meanwhile, HER2-low was an independent risk factor for BCFI in the HR-negative subgroup (hazard ratio, 1.781, 95% confidence interval, 1.061-2.989, P = 0.029).
Conclusion: The clinical biological characteristics of HER2-low IBC-NST could be influenced by the HR status. The clinicopathological features and prognosis of HER2-low and HER2-zero IBC-NST were comparable at the same HR status.